Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157751 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
A Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT04157751 is a Phase 3 study of Heart Failure that has completed, run by Boehringer Ingelheim. The registered enrollment target is 530 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04157751, a Phase 3 study of Heart Failure, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure. Participants are in the study for about 3 months. At the beginning, participants are still in hospital. Later, they visit the hospital about 3 times and get 1 phone call. Participants are put into 2 groups by chance. One group takes 1 empagliflozin tablet a day. The other group takes 1 placebo tablet a day. Placebo tablets look like empagliflozin tablets but do not contain any medicine. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. It is used to treat type 2 diabetes. During the study, the doctors check whether participants have additional heart failure events like needing to go to the hospital again because of heart failure. The participants answer questions about how their heart failure affects their life. We then compare the results between the empagliflozin and placebo groups. The doctors also regularly check the general health of the participants.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Placebo to Empagliflozin
Study Locations (20)
California
- University of Southern California - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine - Orange
- The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
New York
- Erie County Medical Center - Buffalo
- The DeMatteis Center for Cardiac Research and Education - Greenvale
- Stony Brook Medicine - Stony Brook
- Montefiore Medical Center - The Bronx
Florida
- Cardiology Associates Research Co. - Daytona Beach
- University of Florida Health Jacksonville - Jacksonville
New Jersey
- Cardiovascular Associates of the Delaware Valley - Elmer
- Jefferson Washington Township Hospital - Washington Township
Georgia
- Grady Memorial Hospital - Atlanta
Illinois
- Methodist Medical Center - Peoria
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- United Hospital - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2020-05-18 |
| Est. Completion | 2021-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04157751
The ClinicalTrials.gov registry entry for NCT04157751 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (74% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT04157751 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT04157751 about?
NCT04157751 is a clinical study titled "A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure". This is a study in adults who are in hospital for acute heart failure. The purpose of this study is to find out whether starting to take a medicine called empagliflozin soon after first being treated in hospital helps people with acute heart failure. Participants are in the study for about 3 months...
What is the current status of trial NCT04157751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2020-05-18. Estimated completion is 2021-06-02.
What conditions does trial NCT04157751 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT04157751?
The interventions under investigation include: Empagliflozin (DRUG), Placebo to Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT04157751?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04157751 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.